clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-288Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL TRIALSСовременный взгляд на конечные точки для оценки антигипертензивной терапииЛеоноваМ. В.

кафедра клинической фармакологии и фармакокинетики

clinvest@mail.ruФГБОУ ВП РНИМУ им. Н.И. Пирогова Минздрава РоссииRussian Federation200226062008041822Copyright © Леонова М.В., 20182018Леонова М.В.Леонова М.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/288

В конце ХХ века в связи с появлением новых данных эпидемиологических и клинических исследований (КИ) о неблагоприятной роли различных факторов риска на прогноз больных с артериальной гипертонией (АГ) изучение эффективности и безопасности антигипертензивной терапии ассоциировалось с влиянием на «жесткие» («hard») конечные точки (end-points) АГ. Неоспоримой «жесткой» конечной точкой АГ является сердечно-сосудистая смертность; нефатальные сердечно-сосудистые осложнения (острый инфаркт миокарда, инсульт) зачастую включают в эту категорию. Изучение «жестких» конечных точек АГ в КИ не всегда реалистично ввиду их небольшой продолжительности (3-5 лет), особенно в случае включения больных с относительно невысоким риском. В таких случаях для оценки эффективности антигипертензивной терапии в КИ могут быть использованы промежуточные точки, которые называют «суррогатными».

суррогатные конечные точкиконечные точкиартериальная гипертонияантигипертензивная терапияReferencesHansson L. Evaluation of endpoints in hypertension / Blood Pressure 1997, v. 6 (suppl. 2), p. 76-80.Hansson L. Evaluation of endpoints in hypertension / Blood Pressure 1997, v. 6 (suppl. 2), p. 76-80.Collins R., Peto R., McMahon S. et al. Blood pressure, stroke and coronary heart disease. Part II. Shortterm reductions in blood pressure: overview of randomized drug trials in their epidemiological context / Lancet 1990, v. 335, p. 827-838.Collins R., Peto R., McMahon S. et al. Blood pressure, stroke and coronary heart disease. Part II. Shortterm reductions in blood pressure: overview of randomized drug trials in their epidemiological context / Lancet 1990, v. 335, p. 827-838.Culter J.A., Psaty B.M., McMahon S., Furberg C.D. Public health issues in the hypertension control: what has been learned from clinical trials./ In: Hypertension: pathophysiology, diagnosis and management. 2nd ed., N.Y. Raven Press, 1995, p. 253-270.Culter J.A., Psaty B.M., McMahon S., Furberg C.D. Public health issues in the hypertension control: what has been learned from clinical trials./ In: Hypertension: pathophysiology, diagnosis and management. 2nd ed., N.Y. Raven Press, 1995, p. 253-270.Temple R.J. A regulatory authority’s opinion about surrogate endpoints. In: Ed. Nimmo W.S., Tucker G.T. Clinical measurements in drug evaluation. N.Y., J.Wiley, 1995.Temple R.J. A regulatory authority’s opinion about surrogate endpoints. In: Ed. Nimmo W.S., Tucker G.T. Clinical measurements in drug evaluation. N.Y., J.Wiley, 1995.Man A.J., Veld T. Surrogate end points in clinical trials / Blood Pressure 1997, v. 6 (suppl. 2), p. 120-123.Man A.J., Veld T. Surrogate end points in clinical trials / Blood Pressure 1997, v. 6 (suppl. 2), p. 120-123.Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial./ Lancet, 1998, v. 351, p. 1755-1762.Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial./ Lancet, 1998, v. 351, p. 1755-1762.Hosie J., Wiklund I. Managing hypertension in general practice: can we do better? / J. Hum. Hypertens. 1995, v. 9, p. 515-518.Hosie J., Wiklund I. Managing hypertension in general practice: can we do better? / J. Hum. Hypertens. 1995, v. 9, p. 515-518.Mancia G., Frattola A., Ulian L. et al. Blood pressure other than the one at the clinic./ Blood Pressure 1997, v. 6 (suppl. 2), p. 81-85.Mancia G., Frattola A., Ulian L. et al. Blood pressure other than the one at the clinic./ Blood Pressure 1997, v. 6 (suppl. 2), p. 81-85.Mancia G., Zanchetti A., Agabiti8Rosei E. et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy / Circulation 1997, v. 95, p. 1464-1470.Mancia G., Zanchetti A., Agabiti8Rosei E. et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy / Circulation 1997, v. 95, p. 1464-1470.Parati G., Ulian L., Santucciu C. et al. Clinical value of blood pressure variability / Blood Pressure 1997, v. 6 (suppl. 2), p. 91-96.Parati G., Ulian L., Santucciu C. et al. Clinical value of blood pressure variability / Blood Pressure 1997, v. 6 (suppl. 2), p. 91-96.Peter A., Meredith A., Elliott H.L. Evaluation of endpoints in hypertension: blood pressure / Blood Pressure 1997, v. 6 (suppl. 2), p. 86-90.Peter A., Meredith A., Elliott H.L. Evaluation of endpoints in hypertension: blood pressure / Blood Pressure 1997, v. 6 (suppl. 2), p. 86-90.Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham heart study / Drugs 1988, v. 35 (suppl. 5), p. 1-5.Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham heart study / Drugs 1988, v. 35 (suppl. 5), p. 1-5.Strauer B.E., Schwartzkopff B. Left ventricular hypertrophy and coronary microcirculation in hypertensive heart disease / Blood Pressure 1997, v. 6 (suppl. 2), p. 6-12.Strauer B.E., Schwartzkopff B. Left ventricular hypertrophy and coronary microcirculation in hypertensive heart disease / Blood Pressure 1997, v. 6 (suppl. 2), p. 6-12.Agabiti8Rosei E. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment / Blood Pressure 1997, v. 6 (suppl. 2), p. 13-15.Agabiti8Rosei E. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment / Blood Pressure 1997, v. 6 (suppl. 2), p. 13-15.Koren M.J., Savaage D.D., Casale P.N. et al. Changes in left ventricular mass predict risk in essential hypertension./ Circulation 1990, v. 82 (suppl. III), p. 29.Koren M.J., Savaage D.D., Casale P.N. et al. Changes in left ventricular mass predict risk in essential hypertension./ Circulation 1990, v. 82 (suppl. III), p. 29.Jern S. Assessment of left ventricular hypertrophy in patients with essential hypertension / Blood Pressure 1997, v. 6 (suppl. 2), p. 16-23.Jern S. Assessment of left ventricular hypertrophy in patients with essential hypertension / Blood Pressure 1997, v. 6 (suppl. 2), p. 16-23.Dahlof B., Devereux R.B., Faire U. еt al. The losartan intervention for endpoint reduction (LIFE) in hypertension study / Am.J.Hypertens. 1997, v. 10, p. 705-713.Dahlof B., Devereux R.B., Faire U. еt al. The losartan intervention for endpoint reduction (LIFE) in hypertension study / Am.J.Hypertens. 1997, v. 10, p. 705-713.Koren M.J., Devereux R.B., Casale P.N. et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension / Am.Coll.Phys., 1991, v. 114, p. 345-352.Koren M.J., Devereux R.B., Casale P.N. et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension / Am.Coll.Phys., 1991, v. 114, p. 345-352.Muissan M.L., Salvetti M., Rixxoni D. еt al. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline LV mass or systolic performance. A ten years follow-up / J.Hypertens. 1996, v. 14 (suppl. 5), p. s43-s49.Muissan M.L., Salvetti M., Rixxoni D. еt al. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline LV mass or systolic performance. A ten years follow-up / J.Hypertens. 1996, v. 14 (suppl. 5), p. s43-s49.Deverux R.B., Pini R., Aurigemma G.P., Roman M.J. Measurement of left ventricular mass: methodology and expertise / J.Hypertens. 1997, v. 15, p. 801-809.Deverux R.B., Pini R., Aurigemma G.P., Roman M.J. Measurement of left ventricular mass: methodology and expertise / J.Hypertens. 1997, v. 15, p. 801-809.Epstein M., Parving H., Ruiope L.M. Surrogate endpoints and renal protection: focus on microalbuminuria./ Blood Pressure 1997, v. 6 (suppl. 2), p. 52-57.Epstein M., Parving H., Ruiope L.M. Surrogate endpoints and renal protection: focus on microalbuminuria./ Blood Pressure 1997, v. 6 (suppl. 2), p. 52-57.Stephenson J.M., Kenny S., Stevens L.K. et al. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes / Diabet.Med. 1995, v. 12, p. 149-155/Stephenson J.M., Kenny S., Stevens L.K. et al. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes / Diabet.Med. 1995, v. 12, p. 149-155/Agewall S., Wikstrand J., Ljungman S. et al. Does microalbuminuria predict cardiovascular events in non-diabetic men with treated hypertension? Risk factor international study group / Am.J.Hypertens. 1995, v. 8, p. 337-343.Agewall S., Wikstrand J., Ljungman S. et al. Does microalbuminuria predict cardiovascular events in non-diabetic men with treated hypertension? Risk factor international study group / Am.J.Hypertens. 1995, v. 8, p. 337-343.Zanchetti A. Intermediate endpoints for atherosclerosis in hypertension / Blood Pressure 1997, v. 6 (suppl. 2), p. 97-102.Zanchetti A. Intermediate endpoints for atherosclerosis in hypertension / Blood Pressure 1997, v. 6 (suppl. 2), p. 97-102.Zanchetti A., Magnani B., Dal Palu C. on behalf of the VHAS investigators: Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonographic evaluations./ J. Hypertens. 1997, v. 15 (suppl. 4), p. S91.Zanchetti A., Magnani B., Dal Palu C. on behalf of the VHAS investigators: Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonographic evaluations./ J. Hypertens. 1997, v. 15 (suppl. 4), p. S91.Zanchetti A. on behalf of the ELSA investigators. Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA) / Blood Pressure 1996, v. 5 (suppl. 4), p. 30-35.Zanchetti A. on behalf of the ELSA investigators. Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA) / Blood Pressure 1996, v. 5 (suppl. 4), p. 30-35.A joint editorial statement. Diabetes mellitus: a major risk factor for cardiovascular disease / Circulation 1999, v. 100, p. 1132-1133.A joint editorial statement. Diabetes mellitus: a major risk factor for cardiovascular disease / Circulation 1999, v. 100, p. 1132-1133.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38 / Br.Med.J., 1998, v. 317, p. 705-713.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38 / Br.Med.J., 1998, v. 317, p. 705-713.Lithell H.O. Insulin resistance as an intermediary endpoint / Blood Pressure 1997, v. 6 (suppl.2), p. 108-112.Lithell H.O. Insulin resistance as an intermediary endpoint / Blood Pressure 1997, v. 6 (suppl.2), p. 108-112.The CPPP group. The Captopril prevention project: a prospective intervention trial of angiotensine converting enzime inhibition in the treatment of nypertension / J.Hypertens. 1990, v. 8, p. 985-990.The CPPP group. The Captopril prevention project: a prospective intervention trial of angiotensine converting enzime inhibition in the treatment of nypertension / J.Hypertens. 1990, v. 8, p. 985-990.Fossum E., Hoieggen A., Moan A. et al. Insulin sensitivity relates to other cardiovascular risk factors in young men: validation of some modifications of the hyperinsulinaemic, isoglycaemic glucose clamp technique / Blood Pressure 1997, v. 6 (suppl. 2), p. 113-119.Fossum E., Hoieggen A., Moan A. et al. Insulin sensitivity relates to other cardiovascular risk factors in young men: validation of some modifications of the hyperinsulinaemic, isoglycaemic glucose clamp technique / Blood Pressure 1997, v. 6 (suppl. 2), p. 113-119.Hedner T., Sun X. Measures of endothelial function as an endpoint in hypertension? / Blood Pressure 1997, v. 6 (suppl. 2), p. 58-66.Hedner T., Sun X. Measures of endothelial function as an endpoint in hypertension? / Blood Pressure 1997, v. 6 (suppl. 2), p. 58-66.Panza J.A., Quyyumi A.A., Callahan T.S, Epstein S.E. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension /J.Am.Coll.Cardiol. 1993, v. 21, p. 1145-1151.Panza J.A., Quyyumi A.A., Callahan T.S, Epstein S.E. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension /J.Am.Coll.Cardiol. 1993, v. 21, p. 1145-1151.Zwieten P.A.V. Endothelial dysfunction in hypertension. A critical evaluation / Blood Pressure 1997, v. 6 (suppl. 2), p. 67-70.Zwieten P.A.V. Endothelial dysfunction in hypertension. A critical evaluation / Blood Pressure 1997, v. 6 (suppl. 2), p. 67-70.

The authors declare that there are no conflicts of interest present.